
ADHD
Latest News
Latest Videos

Shorts










Podcasts
CME Content
More News

New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.

FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.

Review news in psychiatry from the last week.

Drs Clark and Walton discuss ADHD in underrecognized groups, along with treatment and lifestyle options.

New data on viloxazine ER (Qelbree) show improvements in ADHD, depression, and anxiety in adults, including those who use nicotine or cannabis.

New data show once-daily CTx-1301 delivers 3 timed dexmethylphenidate releases for faster onset, steadier late-day ADHD coverage, tolerability.

FDA clears first triple reuptake ADHD drug Simtriyo, offering nonstimulant relief for adults and kids 6+ with executive and emotional symptoms.

From long-acting antipsychotics to psilocybin and new ADHD meds, clinicians weigh emerging therapies reshaping depression and postpartum care.

FDA clears Simtriyo, a first-in-class NDSRI and central nervous system stimulant for ADHD, offering new symptom and executive-function gains.

Review centanafadine ahead of the upcoming FDA decision on July 24.

Phase 3b trial shows centanafadine eases adult ADHD and anxiety symptoms fast, with expected safety profile, as FDA review nears.

AI analyzes wearable data to reveal objective biomarkers for ADHD and anxiety, enabling passive tracking and earlier psychiatric detection.

FDA issues CRL for CTx-1301 in ADHD.

Weighing the risks and benefits of stimulants to treat ADHD.

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.
























